Thryv Therapeutics
PrivateLast Round
Series B
Sep 17, 2025
Total Funding Raised
$41.74M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Thryv Therapeutics is a biotechnology company that develops precision medicine therapies for genetic arrhythmia syndromes, heart failure, and atrial fibrillation using selective SGK1 inhibitors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Thryv Therapeutics Comparables
Compare Thryv Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Acesion Pharma | 81% | |
| Cardurion Pharmaceuticals | 77% | |
| Milestone Pharmaceuticals Inc. | 72% |
Thryv Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 17, 2025 | ||||
| Convertible Debt | Jun 6, 2023 | ||||
| Series A Extension | Jul 11, 2022 | ||||
| Series A | Aug 10, 2021 | ||||
| Seed | Jan 8, 2020 | ||||
Seed | Nov 6, 2019 |
Thryv Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Amzak Health | Series A |
| Investissement Québec | Convertible Debt |
| CTI Life Sciences Fund | Series B |
| Amplitude Ventures | Series B, Series A |
| Investissement Québec | Series B, Convertible Debt |
| Fonds de solidarité FTQ | Series A, Series B, Seed |
| Alexandria Venture Investments | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 24, 2026
Grew 21% QoQ, from 28 to 34 employees.
- Aug 22, 2026
Monthly visitors increased 37% MoM.
Thryv Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Thryv Therapeutics's valuation, stock price, and market status.
Is Thryv Therapeutics a public or private company?
Thryv Therapeutics is a private company.
What is the current stock price of Thryv Therapeutics?
Thryv Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Thryv Therapeutics worth (valuation)?
Valuation information for Thryv Therapeutics is not publicly available.
Can I buy Thryv Therapeutics stock?
Thryv Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Thryv Therapeutics's last funding round?
Thryv Therapeutics's most recent funding round was Series B on September 17, 2025.
Who are the main investors in Thryv Therapeutics?
Key investors in Thryv Therapeutics include Amplitude Ventures, Investissement Québec, Fonds de solidarité FTQ.
Will Thryv Therapeutics IPO soon?
No public IPO plans have been announced for Thryv Therapeutics.
How can I track Thryv Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Thryv Therapeutics's secondary market activity and sign up for updates.